deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT04644289

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (WoO)

Window-of-opportunity Proof-of-concept, Non-randomized, Open-label Phase II Trial of Olaparib Given Alone (Cohort A) or in Combination With Durvalumab (Cohort B) Prior to Primary Debulking Surgery in Histologically Proven High-grade Epithelial Ovarian Cancer (EOC)

Sponsor: AGO Research GmbH

Conditions Epithelial Ovarian Cancer
Interventions durvalumab olaparib
Updated 15 times since 2020 Last updated: Sep 30, 2025 Started: May 5, 2022 Primary completion: Jan 31, 2028 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Epithelial Ovarian Cancer, this trial is actively recruiting participants. The trial is conducted by AGO Research GmbH and has accumulated 15 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Feb 2023 · 7 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Jun 2025 · 3 months · monthly snapshot~Jun 2025 – ~Nov 2025 · 5 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

15 versions recorded

  1. Nov 2025 — Present [monthly]

    Recruiting PHASE2

  2. Jun 2025 — Nov 2025 [monthly]

    Recruiting PHASE2

  3. Mar 2025 — Jun 2025 [monthly]

    Recruiting PHASE2

  4. Sep 2024 — Mar 2025 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

▶ Show 10 earlier versions

  1. Jun 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

  2. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  3. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  4. Jul 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  5. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  6. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jan 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE2

  8. Sep 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE2

  9. Jan 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2

  10. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AGO Research GmbH
Data source: AGO Research GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations